| Trial ID: | L0036 |
| Source ID: | NCT03884075
|
| Associated Drug: |
Semaglutide
|
| Title: |
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-Alcoholic Steatohepatitis|Non-Alcoholic Fatty Liver Disease
|
| Interventions: |
Drug: Semaglutide
|
| Outcome Measures: |
Histological Improvement|Clinical Improvement|Change in hepatic gene expression
|
| Sponsor/Collaborators: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
|
| Gender: |
All
|
| Age: |
18 Years and older ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
84
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
|
| Start Date: |
July 24, 2019
|
| Completion Date: |
January 31, 2023
|
| Results First Posted: |
--
|
| Last Update Posted: |
March 18, 2022
|
| Locations: |
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT03884075
|
